NASDAQ:IBRX | Free Cash Flow | ImmunityBio, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2013-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$75.36M$1.78M-$77.14M
2025-12-31-$70.38M$903,000.00-$71.28M
2025-03-31-$85.91M$1.12M-$87.03M
2024-12-31-$85.14M$2.11M-$87.26M
2024-03-31-$106.98M$1.26M-$108.24M
2023-12-31-$115.27M$7.96M-$123.23M
2023-03-31-$84.31M$8.43M-$92.74M
2022-12-31-$90.73M$18.93M-$109.66M
2022-03-31-$74.93M$27.35M-$102.28M
2021-12-31-$71.64M$10.4M-$82.04M
2021-03-31-$60.47M$7.08M-$67.55M
2020-12-31-$57.6M-$699,000.00-$58.3M
2020-03-31-$31.11M$315,000.00-$31.42M
2019-12-31-$105.63M$785,000.00-$106.42M
2019-03-31-$13.08M$2.1M-$15.18M
2018-12-31-$14.03M$2.05M-$16.08M
2018-03-31-$15.51M$4.9M-$20.41M
2017-12-31-$13.64M$11.43M-$25.07M
2017-03-31-$10.06M$4.51M-$14.57M
2016-12-31-$10.75M$1.36M-$12.11M
2016-03-31-$8.86M$1.07M-$9.92M
2015-12-31-$10.94M$955,000.00-$11.9M
2015-03-31-$7.37M$38,000.00-$7.41M
2014-12-31-$2.57M$37,000.00-$2.61M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$304.94M$3.85M-$308.78M
2024-12-31-$391.24M$6.89M-$398.12M
2023-12-31-$366.76M$30.58M-$397.34M
2022-12-31-$337.51M$78.16M-$415.67M
2021-12-31-$274.42M$33.56M-$307.98M
2020-12-31-$171.72M$1.67M-$173.39M
2019-12-31-$152.11M$4.29M-$156.4M
2018-12-31-$63.38M$13.1M-$76.48M
2017-12-31-$48.78M$34.82M-$83.6M
2016-12-31-$38.59M$6.56M-$45.15M
2015-12-31-$25.31M$2.24M-$27.55M
2014-12-31-$5.42M$235,000.00-$5.65M
2013-12-31-$668,000.00$3,000.00-$671,000.00